Tepotinib for Advanced Solid Cancers Harboring MET Exon 14 Skipping Mutations or Amplifications
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17)
ESMO Open 2024 Aug 29;9(9)103668, EJ Kang, Y Yang, S Lee, YJ Kim, SM Lim, MJ Ahn, YJ Choi, Y Lee, TM Kim, I Kim, HK Ahn, HC Jeung, SI Lee, SY Oh, WK Bae, H Ryu, KH Park, KH LeeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.